Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 5
1951 6
1952 1
1953 1
1955 2
1956 1
1964 3
1965 3
1966 1
1967 2
1968 1
1972 1
1973 1
1975 1
1976 1
1977 2
1979 1
1980 3
1981 3
1983 3
1984 3
1986 1
1987 2
1988 2
1989 3
1993 1
1994 1
1995 3
1996 1
1998 1
2002 4
2003 6
2004 6
2005 2
2006 6
2007 1
2008 6
2009 6
2010 13
2011 6
2012 8
2013 13
2014 13
2015 15
2016 10
2017 7
2018 7
2019 7
2020 8
2021 5
2022 7
2023 6
2024 9
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

223 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Asoori Maringanti S, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD Jr, Richard S, Martin T, Lin Y, Patel KK, Sidana S; US Multiple Myeloma Immunotherapy Consortium. Hansen DK, et al. Among authors: atanackovic d. J Clin Oncol. 2025 May;43(13):1597-1609. doi: 10.1200/JCO-24-01730. Epub 2025 Feb 18. J Clin Oncol. 2025. PMID: 39965175
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri C, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo R, Nadeem O, Mann H, Kalariya N, Hovanky V, De Avila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr M, Htut M, McGuirk J, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Sidana S, et al. Among authors: atanackovic d. Blood. 2025 Jan 2;145(1):85-97. doi: 10.1182/blood.2024025945. Blood. 2025. PMID: 39365257
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.
Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, Atrash S, Bachanova V, Beitinjaneh AM, Bhurtel E, Castaneda Puglianini O, Chhabra S, Cicero KI, Davis JA, Dhakal B, Dima D, Ferreri CJ, Forsberg PA, Freeman CL, Herr MM, Jain T, Janakiram M, Khouri J, Kocoglu MH, Kumar A, Liu Y, Locke F, McGuirk JP, Mikkilineni L, Nadeem O, Parrondo RD, Pasvolsky O, Peres LC, Purvey S, Raza S, Reshef R, Richard S, Rossi AC, Sborov DW, Shune L, Wagner CB, Zanwar SS, Sidana S, Patel KK, Hansen DK, Kumar SK, Lin Y, Martin TG, Voorhees PM, Anderson LD Jr, Cowan AJ, Kaur G. Banerjee R, et al. Among authors: atanackovic d. Blood Adv. 2025 May 13;9(9):2336-2340. doi: 10.1182/bloodadvances.2025016131. Blood Adv. 2025. PMID: 40088469 Free PMC article. No abstract available.
Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.
Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Maringanti SA, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD Jr, Richard S, Martin T, Lin Y, Patel KK, Sidana S; US Multiple Myeloma Immunotherapy Consortium. Hansen DK, et al. Among authors: atanackovic d. J Clin Oncol. 2025 Apr 10;43(11):1399. doi: 10.1200/JCO-25-00453. Epub 2025 Mar 7. J Clin Oncol. 2025. PMID: 40053892 No abstract available.
Role of immunotherapy in Ewing sarcoma.
Morales E, Olson M, Iglesias F, Dahiya S, Luetkens T, Atanackovic D. Morales E, et al. Among authors: atanackovic d. J Immunother Cancer. 2020 Dec;8(2):e000653. doi: 10.1136/jitc-2020-000653. J Immunother Cancer. 2020. PMID: 33293354 Free PMC article. Review.
Extracellular vesicles containing SARS-CoV-2 proteins are associated with multi-organ dysfunction and worse outcomes in patients with severe COVID-19.
de Miguel-Perez D, Arroyo-Hernandez M, La Salvia S, Gunasekaran M, Pickering EM, Avila S, Gebru E, Becerril-Vargas E, Monraz-Perez S, Saharia K, Grazioli A, McCurdy MT, Frieman M, Miorin L, Russo A, Cardona AF, García-Sastre A, Kaushal S, Hirsch FR, Atanackovic D, Sahoo S, Arrieta O, Rolfo C. de Miguel-Perez D, et al. Among authors: atanackovic d. J Extracell Vesicles. 2024 Nov;13(11):e70001. doi: 10.1002/jev2.70001. J Extracell Vesicles. 2024. PMID: 39558820 Free PMC article.
Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy.
Atanackovic D, Luetkens T, Omili D, Iraguha T, Lutfi F, Hardy NM, Fan X, Avila SV, Saharia KK, Husson JS, Niederhaus SV, Margiotta P, Lee ST, Law JY, Mannuel HD, Vander Mause E, Bauman S, Lesho P, Hankey K, Baddley J, Kocoglu M, Yared JA, Rapoport AP, Dahiya S. Atanackovic D, et al. Blood. 2022 Jul 14;140(2):152-156. doi: 10.1182/blood.2022016175. Blood. 2022. PMID: 35537186 Free PMC article.
Immunotherapies targeting CD38 in Multiple Myeloma.
Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T. Atanackovic D, et al. Oncoimmunology. 2016 Aug 5;5(11):e1217374. doi: 10.1080/2162402X.2016.1217374. eCollection 2016. Oncoimmunology. 2016. PMID: 27999737 Free PMC article. Review.
Elotuzumab as a novel anti-myeloma immunotherapy.
Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D. Radhakrishnan SV, et al. Among authors: atanackovic d. Hum Vaccin Immunother. 2017 Aug 3;13(8):1751-1757. doi: 10.1080/21645515.2017.1327487. Epub 2017 Jun 12. Hum Vaccin Immunother. 2017. PMID: 28604269 Free PMC article. Review.
223 results